Literature DB >> 16938519

The close relationship between heparanase and cyclooxygenase-2 expressions in signet-ring cell carcinoma of the stomach.

Yasuyuki Ohtawa1, Yoshio Naomoto, Yasuhiro Shirakawa, Munenori Takaoka, Toshihiro Murata, Ryotaro Sonoda, Kazufumi Sakurama, Tomoki Yamatsuji, Mehmet Gunduz, Hidetsugu Tsujigiwa, Hitoshi Nagatsuka, Norihiko Terada, Satoshi Itano, Sadayuki Horiki, Kazuyoshi Yanagihara, Motowo Nakajima, Noriaki Tanaka.   

Abstract

Signet-ring cell carcinoma (SRC) of the stomach exhibits diffuse growth and invasion without forming ducts. Destruction of the surrounding basal membrane and angiogenesis appear to be required for SRC to exhibit marked invasion and growth. We recently reported that heparanase (HPA) and cyclooxygenase-2 (COX-2) were strongly correlated with microvessel density, and that COX-2 expression is up-regulated by HPA in esophageal cancer. In this study, we examined the relationship between HPA expression and that of COX-2 in SRC of the stomach. We examined HPA and COX-2 expression in 3 cell lines derived from SRC of the stomach and in 50 SRC lesions of stomach by immunohistochemistry (IHC), in situ hybridization, and reverse transcriptase-polymerase chain reaction (RT-PCR). We also examined the relationships among HPA expression, COX-2 expression, and the clinicopathologic features of SRC, mean age, sex, invasion depth, regional lymph node metastasis, lymphatic invasion, and venous blood vessel invasion. Of the 3 cell lines, 2 exhibited both HPA and COX-2 mRNA expression on RT-PCR. Of the 3 cell lines, 1 exhibited only HPA mRNA expression on RT-PCR. Heparanase expression was confirmed in 23 (46%) of 50 tumor samples by IHC. COX-2 expression was confirmed in 25 (50%) of the 50 tumor samples by IHC. In situ hybridization revealed messenger RNA expression in the same area as in that revealed by IHC. A close correlation was noted between HPA and COX-2 expressions (P < .0001). The present study thus elucidated the biologic features of SRC of the stomach related to growth and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16938519     DOI: 10.1016/j.humpath.2006.04.005

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases.

Authors:  K A Paschos; D Canovas; N C Bird
Journal:  Hippokratia       Date:  2009-01       Impact factor: 0.471

2.  Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy.

Authors:  Jun Zhang; Jianmin Yang; Xiaomei Han; Zhongsheng Zhao; Ling DU; Tong Yu; Huiju Wang
Journal:  Oncol Lett       Date:  2012-05-04       Impact factor: 2.967

3.  Heparanase-1 and Cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas.

Authors:  Yu Zhu; Hong-chao He; Fei Yuan; Jun Zhang; Wen-bin Rui; Ju-ping Zhao; Zhou-jun Shen; Guang Ning
Journal:  Endocrine       Date:  2010-06-18       Impact factor: 3.633

4.  Expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma: correlation with pathological parameters in 110 patients.

Authors:  Sarfraz Ali; Qiqin Yin-Goen; Timothy V Johnson; Wei Han; Nicole A Johnson; Wayne B Harris; Fray F Marshall; Andrew N Young; Viraj A Master; Adeboye O Osunkoya
Journal:  Tumour Biol       Date:  2010-11-18

Review 5.  Heparanase: a target for drug discovery in cancer and inflammation.

Authors:  E A McKenzie
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

6.  An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation.

Authors:  Xiaoyan Liu; Hong Fang; Hongchao Chen; Xiaoling Jiang; Deren Fang; Yan Wang; Dingxian Zhu
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

Review 7.  Mammalian heparanase: what is the message?

Authors:  Veronique Vreys; Guido David
Journal:  J Cell Mol Med       Date:  2007 May-Jun       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.